Q&A: Did CMS change its packaging of skin substitutes in the latest OPPS update?
APCs Insider, April 18, 2014
Want to receive articles like this one in your inbox? Subscribe to APCs Insider!
Q: Did CMS issue any new HCPCS codes for drugs and biologicals for April 2014?
A: CMS added one new HCPCS code for a monoclonal antibody effective April 1. HCPCS code C9021 (Injection, obinutuzumab, 10) is assigned status indicator G (pass-through drugs and biologicals; separate APC payment). This was not detailed in Transmittal 2903 but was noted in the Business Requirements Table and in Transmittal 2900, the April 2014 update to the I/OCE.
In addition, Transmittal 2900 notes that the status indicator for HCPCS code Q4121 (Theraskin) has changed from N (packaged) to G ) effective April 1, 2014. If this skin substitute is used, the APC payment will be subject to the device offset as separate payment will be made for the line item.
Editor’s note: Denise Williams, RN, CPC-H, vice president of revenue integrity services at Health Revenue Assurance Associates, Inc., in Plantation, Fla., answered this question.
Want to receive articles like this one in your inbox? Subscribe to APCs Insider!
Related Products
Most Popular
- Articles
-
- Don't forget the three checks in medication administration
- Nursing responsibilities for managing pain
- Complications from immobility by body system
- Q&A: Primary, principal, and secondary diagnoses
- Practice the six rights of medication administration
- The consequences of an incomplete medical record
- Note similarities and differences between HCPCS, CPT® codes
- Skills of effective case managers
- Neurological checks for head injuries
- Prevent dehydration with nursing interventions
- E-mailed
- Searched